Sean Sullivan

Sean Sullivan

Company: Arcturus Therapeutics

Job title: Executive Director

Seminars:

Pre-Clinical and Clinical Development of a Next-Generation mRNA COVID-19 Vaccine 11:45 am

Preliminary preclinical results for second generation vaccines designed with improved anti-viral immunogenicity exhibited cross neutralizationagainst alpha, beta, gamma and delta circulating viral variants in mice and non-human primates Rhesus macaque immunogenicity studies showed high neutralizing antibody titers after two prime injections 28 days apart A further increase in neutralizing antibody titers were observed with a…Read more

day: Day One Morning

Pre-Clinical Development of a Next-Generation mRNA Vaccine for Influenza 9:00 am

Preliminary preclinical results for second generation vaccines designed with improved anti-viral immunogenicity exhibited cross neutralization against alpha, beta, gamma and delta circulating viral variants in mice and non-human primates Rhesus macaque immunogenicity studies showed high neutralizing antibody titers after two prime injections 28 days apart. A further increase in neutralizing antibody titers were observed with…Read more

day: Pre-Conference Focus Day: Respiratory Infectious Disease Vaccine Development

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.